Plain-English translation of NCT07483346 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called IASO-782 in people with systemic lupus erythematosus (SLE), an autoimmune condition where your body's immune system attacks its own tissues. The study will give some participants the new medication and others a placebo (inactive injection) to see if the treatment is safe, how the body processes it, and whether it helps reduce lupus symptoms. Researchers will carefully monitor participants to understand the right dose and watch for any side effects.
Currently available lupus treatments don't work well enough for everyone, and some people experience troubling side effects. This medication may offer a new option to help control lupus and reduce the damage it causes to the body.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive three injections of either the new medication or a placebo on days 1, 8, and 15 of the study. Between injections, you'll visit the clinic for safety checks and blood tests to see how your body is responding. The entire active treatment phase lasts about two weeks, though researchers will continue monitoring you afterward. You'll continue taking your regular lupus medications throughout the study.
AI-generated summary from trial data ยท Aug 12, 2026 ยท Not medical advice
China